Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
Tyra Biosciences (Nasdaq: TYRA) has announced that its late-breaking abstract about TYRA-300 has been accepted for presentation at ENDO 2025, scheduled for July 12-15, 2025 in San Francisco. The poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be presented by Dr. Jacqueline H. Starrett on July 13, 2025.
The presentation will be part of Session P70, focusing on bone and mineral metabolism, specifically rare bone and genetic disorders. The poster will be available on Tyra's investor relations website following the conference.
Tyra Biosciences (Nasdaq: TYRA) ha annunciato che il suo abstract di ultima ora riguardante TYRA-300 猫 stato accettato per la presentazione a ENDO 2025, in programma dal 12 al 15 luglio 2025 a San Francisco. La presentazione poster, intitolata "TYRA-300 favorisce la crescita ossea in due modelli murini di displasia scheletrica correlata a FGFR3", sar脿 presentata dalla Dott.ssa Jacqueline H. Starrett il 13 luglio 2025.
La presentazione far脿 parte della Sessione P70, dedicata al metabolismo osseo e minerale, con particolare attenzione a malattie ossee rare e genetiche. Il poster sar脿 disponibile sul sito web delle relazioni con gli investitori di Tyra dopo la conferenza.
Tyra Biosciences (Nasdaq: TYRA) ha anunciado que su resumen de 煤ltima hora sobre TYRA-300 ha sido aceptado para su presentaci贸n en ENDO 2025, programado del 12 al 15 de julio de 2025 en San Francisco. La presentaci贸n en formato p贸ster, titulada "TYRA-300 promueve el crecimiento 贸seo en dos modelos de rat贸n con displasia esquel茅tica relacionada con FGFR3", ser谩 presentada por la Dra. Jacqueline H. Starrett el 13 de julio de 2025.
La presentaci贸n formar谩 parte de la Sesi贸n P70, centrada en el metabolismo 贸seo y mineral, espec铆ficamente en trastornos 贸seos raros y gen茅ticos. El p贸ster estar谩 disponible en el sitio web de relaciones con inversores de Tyra despu茅s de la conferencia.
Tyra Biosciences (雮橃姢雼�: TYRA)电� TYRA-300鞐� 甏�頃� 旮搓笁 齑堧鞚� 2025雲� 7鞗� 12鞚茧秬韯� 15鞚缄箤歆� 靸岉攧霝�鞁滌姢旖旍棎靹� 鞐措Μ电� ENDO 2025鞐愳劀 氚滍憸霅� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟. "TYRA-300鞚� FGFR3 甏�霠� 瓿博 鞚错槙靹膘 霊� 毵堨毎鞀� 氇嵏鞐愳劀 爰� 靹膘灔 齑夓"鞚措澕电� 鞝滊鞚� 韽姢韯� 氚滍憸电� 2025雲� 7鞗� 13鞚� Dr. Jacqueline H. Starrett臧� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
鞚� 氚滍憸电� 爰� 氚� 氙鸽劋霝� 雽�靷棎 齑堨爯鞚� 毵烄稑 P70 靹胳厴鞚� 鞚茧秬搿�, 頋穩 瓿博 氚� 鞙犾爠 歆堩櫂鞚� 雼る９雼堧嫟. 韽姢韯暗鐢 頃欗殞 頉� Tyra 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Tyra Biosciences (Nasdaq : TYRA) a annonc茅 que son r茅sum茅 de derni猫re minute concernant TYRA-300 a 茅t茅 accept茅 pour pr茅sentation 脿 ENDO 2025, pr茅vu du 12 au 15 juillet 2025 脿 San Francisco. La pr茅sentation sous forme d'affiche, intitul茅e "TYRA-300 favorise la croissance osseuse dans deux mod猫les murins de dysplasie squelettique li茅e 脿 FGFR3", sera pr茅sent茅e par le Dr Jacqueline H. Starrett le 13 juillet 2025.
Cette pr茅sentation fera partie de la session P70, ax茅e sur le m茅tabolisme osseux et min茅ral, en particulier les troubles osseux rares et g茅n茅tiques. L'affiche sera disponible sur le site des relations investisseurs de Tyra apr猫s la conf茅rence.
Tyra Biosciences (Nasdaq: TYRA) hat bekanntgegeben, dass sein kurzfristig eingereichtes Abstract zu TYRA-300 f眉r eine Pr盲sentation auf der ENDO 2025 angenommen wurde, die vom 12. bis 15. Juli 2025 in San Francisco stattfindet. Die Posterpr盲sentation mit dem Titel "TYRA-300 f枚rdert das Knochenwachstum in zwei Mausmodellen der FGFR3-bedingten Skelettdysplasie" wird von Dr. Jacqueline H. Starrett am 13. Juli 2025 vorgestellt.
Die Pr盲sentation ist Teil der Sitzung P70, die sich auf Knochen- und Mineralstoffwechsel konzentriert, insbesondere auf seltene Knochen- und genetische Erkrankungen. Das Poster wird nach der Konferenz auf der Investor-Relations-Webseite von Tyra verf眉gbar sein.
- None.
- None.
Details of the poster presentation are below:
- Title: "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia"
- Abstract: SUN-730
- Presenting Author: Jacqueline H. Starrett, Ph.D., Tyra Biosciences
- Date/Time: July 13, 2025, 12:00 PM - 1:30 PM, ENDOExpo: Poster Area
- Session: Session P70 - BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders
More information on ENDO 2025 can be found at the meeting website. The聽TYRA poster at ENDO 2025 will be available here following the conference: .
About TYRA-300
TYRA-300 is the Company's lead precision medicine program stemming from its in-house SN脜P platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia that has demonstrated interim clinical proof-of-concept results in metastatic urothelial cancer (mUC). TYRA-300's planned clinical development includes three Phase 2 clinical trials: SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC), BEACH301 for pediatric achondroplasia and SURF301 for mUC.聽
Please visit the聽Patients聽page of our website for more information on our clinical trials.
About聽Tyra Biosciences
Tyra Biosciences, Inc.聽(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SN脜P, enables rapid and precise drug design through iterative molecular SN脜Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from聽SN脜P, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for mUC. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in聽Carlsbad, CA.
For more information about our science, pipeline and people, please visit聽www.tyra.bio聽and engage with us on聽LinkedIn.
Contact:
Amy Conrad
[email protected]
View original content to download multimedia:
SOURCE Tyra Biosciences
FAQ
When and where will Tyra Biosciences (TYRA) present its TYRA-300 research at ENDO 2025?
What is the focus of Tyra Biosciences' (TYRA) poster presentation at ENDO 2025?
Who will present Tyra Biosciences' (TYRA) research at ENDO 2025?
Where can investors access Tyra Biosciences' (TYRA) ENDO 2025 poster presentation?
